Abstract
Enoxacin and lomefloxacin were found to display a biphasic response when their bactericidal activities were investigated againstEscherichia coli KL16 in nutrient broth. Although enoxacin required bacterial protein and RNA synthesis to exert bactericidal activity, it was able to kill non-dividing bacteria. On the other hand, the protein synthesis inhibitor chloramphenicol and the RNA synthesis inhibitor rifampicin did not abolish enoxacin's killing activity againstEscherichia coli KL16 in nutrient broth. Lomefloxacin was also shown to be active against non-dividingEscherichia coli KL16.
Similar content being viewed by others
References
Reeves, D. S., Bywater, M. J., Marshall, P. W.: The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents and factors affecting that activity. Journal of Antimicrobial Chemotherapy 1984, 14, Supplement C: 7–18.
Siporin, C., Towse, G.: Enoxacin: worldwide in vitro activity against 22,451 clinical isolates. Journal of Antimicrobial Chemotherapy 1984, 14, Supplement C: 47–56.
Finch, R., Martin, J., Pilkington, R.: In vitro assessment of lomefloxacin (SC-47111) — a new quinolone derivative. Journal of Antimicrobial Chemotherapy 1988, 22: 881–884.
Edwards, R., Kanematsu, M., Greenwood, D.: Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin. Journal of Antimicrobial Chemotherapy 1988, 22: 885–890.
Smith, J. T.: Awakening the slumbering potential of the 4-quinolone antibiotics. Pharmaceutical Journal 1984, 233: 299–305.
Smith, J. T., Lewin, C. S.: Chemistry and mechanisms of action of the quinolone antibacterials. In: Andriole, V. T. (ed.): The quinolones. Academic Press, London, 1988, p. 23–82.
Dietz, W. H., Cook, T. M., Goss, W. A.: Mechanism of action of nalidixic acid onEscherichia coli. III: Conditions required for lethality. Journal of Bacteriology 1966, 94: 768–773.
Zeiler, H.-J., Grohe, K.: The in vitro and in vivo activity of ciprofloxacin. European Journal of Clinical Microbiology 1984, 4: 339–343.
Piddock, L. J. V., Andrews, J. M., Diver, J. M., Wise, R.: In vitro studies of S25930 and S25932, two new 4-quinolones. European Journal of Clinical Microbiology 1986, 5: 303–310.
Lewin, C. S., Howard, B. M. A., Ratcliffe, N. T., Smith, J. T.: 4-quinolones and the SOS response. Journal of Medical Microbiology 1989, 29: 139–144.
Lewin, C. S., Smith, J. T.: Bactericidal mechanisms of ofloxacin. Journal of Antimicrobial Chemotherapy 1988, 22, Supplement C: 1–8.
Chang, T., Black, A., Dunky, A., Wolf, R., Sedman, A., Latts, J., Welling, P. G.: Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 1988, 21, Supplement B: 49–56.
Morrison, P. J., Mant, T. G. K., Norman, G. T., Robinson, J., Kunka, R. L.: Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. Antimicrobial Agents and Chemotherapy 1988, 32: 1503–1507.
Stone, J. W., Andrews, J. M., Ashby, J. P., Griggs, D., Wise, R.: Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrobial Agents and Chemotherapy 1988, 32: 1508–1510.
Ratcliffe, N. T., Smith, J. T.: Norfloxacin has a novel bactericidal mechanism unrelated to that of other 4-quinolones. Journal of Pharmacy and Pharmacology 1985, 37: 92.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lewin, C.S., Amyes, S.G.B. & Smith, J.T. Bactericidal activity of enoxacin and Lomefloxacin againstEscherichia coli KL16. Eur. J. Clin. Microbiol. Infect. Dis. 8, 731–733 (1989). https://doi.org/10.1007/BF01963763
Issue Date:
DOI: https://doi.org/10.1007/BF01963763